drugset / Trial / NCT03757234
IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study was to evaluate the safety and efficacy of intravenous (iv) or iv/per oral (po) omadacycline as compared to iv or iv/po levofloxacin in the treatment of female adults with acute pyelonephritis.
Timeline
- Start
- 2018-11-19
- Primary completion
- 2019-06-26
- Completion
- 2019-07-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Levofloxacin | Small molecule | 750 mg | Intravenous |
| Subject | Omadacycline | Small molecule | 100 mg | Intravenous |
| Subject | Omadacycline | Small molecule | 200 mg | Intravenous |
| Subject | Omadacycline | Small molecule | 300 mg | Intravenous |
| Subject | Omadacycline | Small molecule | 450 mg | Intravenous |